These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30352798)

  • 1. Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8
    Clancy-Thompson E; Devlin CA; Tyler PM; Servos MM; Ali LR; Ventre KS; Bhuiyan MA; Bruck PT; Birnbaum ME; Dougan SK
    Cancer Immunol Res; 2018 Dec; 6(12):1524-1536. PubMed ID: 30352798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.
    Dougan SK; Dougan M; Kim J; Turner JA; Ogata S; Cho HI; Jaenisch R; Celis E; Ploegh HL
    Cancer Immunol Res; 2013 Aug; 1(2):99-111. PubMed ID: 24459675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
    Liu Y; Peng Y; Mi M; Guevara-Patino J; Munn DH; Fu N; He Y
    J Immunol; 2009 May; 182(10):5960-9. PubMed ID: 19414747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.
    Doody AD; Kovalchin JT; Mihalyo MA; Hagymasi AT; Drake CG; Adler AJ
    J Immunol; 2004 May; 172(10):6087-92. PubMed ID: 15128793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.
    Watson AM; Mylin LM; Thompson MM; Schell TD
    J Immunol; 2012 Dec; 189(12):5549-60. PubMed ID: 23175697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immunity from naive CD8+ T cells activated in vitro with MHC class I binding immunogenic peptides and IL-2 in the absence of specialized APCs.
    Hauser C; Zipprich F; Leblond I; Wirth S; Hügin AW
    J Immunol; 1999 Jul; 163(1):330-6. PubMed ID: 10384132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
    Martínez-Usatorre A; Donda A; Zehn D; Romero P
    J Immunol; 2018 Jul; 201(2):792-803. PubMed ID: 29875150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen.
    Rausch MP; Hastings KT
    PLoS One; 2015; 10(4):e0123332. PubMed ID: 25875653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient loss of MHC class I tetramer binding after CD8+ T cell activation reflects altered T cell effector function.
    Drake DR; Ream RM; Lawrence CW; Braciale TJ
    J Immunol; 2005 Aug; 175(3):1507-15. PubMed ID: 16034088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A low affinity TCR ligand restores positive selection of CD8+ T cells in vivo.
    Stefanski HE; Mayerova D; Jameson SC; Hogquist KA
    J Immunol; 2001 Jun; 166(11):6602-7. PubMed ID: 11359813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H1 on hepatocytes facilitates priming of specific CD8 T cells but limits the specific recall of primed responses.
    Wahl C; Bochtler P; Chen L; Schirmbeck R; Reimann J
    Gastroenterology; 2008 Sep; 135(3):980-8. PubMed ID: 18621049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses.
    Umeshappa CS; Huang H; Xie Y; Wei Y; Mulligan SJ; Deng Y; Xiang J
    J Immunol; 2009 Jan; 182(1):193-206. PubMed ID: 19109150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
    Bullock TN; Mullins DW; Colella TA; Engelhard VH
    J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity.
    Prins RM; Incardona F; Lau R; Lee P; Claus S; Zhang W; Black KL; Wheeler CJ
    J Immunol; 2004 Feb; 172(3):1602-11. PubMed ID: 14734741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I.
    Griffiths E; Ong H; Soloski MJ; Bachmann MF; Ohashi PS; Speiser DE
    Cancer Res; 1998 Oct; 58(20):4682-7. PubMed ID: 9788622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM; Winter H; Urba WJ; Fox BA
    J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.
    Soto CM; Stone JD; Chervin AS; Engels B; Schreiber H; Roy EJ; Kranz DM
    Cancer Immunol Immunother; 2013 Feb; 62(2):359-69. PubMed ID: 22926060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity.
    Kureshi R; Bello E; Kureshi CTS; Walsh MJ; Lippert V; Hoffman MT; Dougan M; Longmire T; Wichroski M; Dougan SK
    Sci Adv; 2023 Nov; 9(47):eadk1853. PubMed ID: 38000024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.